Loading...
XASX
CUV
Market cap349mUSD
Jul 11, Last price  
10.58AUD
1D
1.05%
1Q
-0.19%
Jan 2017
42.01%
IPO
753.23%
Name

Clinuvel Pharmaceuticals Ltd

Chart & Performance

D1W1MN
P/E
14.88
P/S
6.01
EPS
0.71
Div Yield, %
0.47%
Shrs. gr., 5y
0.57%
Rev. gr., 5y
23.22%
Revenues
88m
+12.59%
124,622754,846283,3080001,041,021722,8011,552,9982,663,1103,317,6796,820,39816,765,45625,485,82031,047,77632,565,42347,975,58365,722,29178,321,31888,178,308
Net income
36m
+16.44%
-11,029,031-10,768,981-9,176,123-14,655,791-15,372,907-11,521,040-11,409,089-9,767,228-6,802,823-5,525,889-10,398,033-3,121,2007,180,82713,224,18518,134,16016,646,85924,728,24720,878,46530,604,56635,636,359
CFO
37m
+0.38%
-9,246,356-11,403,457-8,178,814-7,181,333-10,985,544-11,782,745-9,486,857-10,022,681-6,892,066-4,808,685-4,529,812-5,036,9339,916,93611,693,33318,456,10714,188,36819,262,06139,872,28236,912,06337,053,882
Dividend
Sep 05, 20240.05 AUD/sh
Earnings
Aug 18, 2025

Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
IPO date
Feb 13, 2001
Employees
16
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
88,178
12.59%
78,321
19.17%
Cost of revenue
39,030
37,412
Unusual Expense (Income)
NOPBT
49,148
40,910
NOPBT Margin
55.74%
52.23%
Operating Taxes
15,043
14,974
Tax Rate
30.61%
36.60%
NOPAT
34,106
25,936
Net income
35,636
16.44%
30,605
46.58%
Dividends
(2,470)
(1,976)
Dividend yield
0.31%
0.21%
Proceeds from repurchase of equity
(754)
BB yield
0.10%
Debt
Debt current
370
(15,793)
Long-term debt
1,390
1,398
Deferred revenue
Other long-term liabilities
164
3,700
Net debt
(182,243)
(174,060)
Cash flow
Cash from operating activities
37,054
36,912
CAPEX
(5,576)
(1,028)
Cash from investing activities
(29,034)
(1,028)
Cash from financing activities
(3,572)
(2,240)
FCF
23,737
7,736
Balance
Cash
183,868
156,814
Long term investments
134
2,851
Excess cash
179,594
155,749
Stockholders' equity
203,011
164,631
Invested Capital
24,461
10,014
ROIC
197.86%
594.33%
ROCE
23.83%
24.16%
EV
Common stock shares outstanding
51,027
51,816
Price
15.37
-14.04%
17.88
20.40%
Market cap
784,281
-15.35%
926,470
20.50%
EV
602,037
752,410
EBITDA
50,290
41,699
EV/EBITDA
11.97
18.04
Interest
4,454
3,193
Interest/NOPBT
9.06%
7.80%